This product is a white freeze-dried powder. After dissolving, it becomes a clear colorless liquid with no visible particles. Main ingredients: peginterferon α2b Excipients: disodium hydrogen phosphate, sodium dihydrogen phosphate, sucrose, polysorbate 80 and water for injection.

[PegIntron Leneng Indications】

1. Chronic Hepatitis C This product is suitable for the treatment of chronic hepatitis C. Patients must be ≥18 years old and have compensated liver disease. It is now believed that the ideal treatment for chronic hepatitis C is the combination of this product and ribavirin. When this product is used together with ribavirin, please also refer to the product information for ribavirin.

2. Chronic hepatitis B This product can also be used to treat HBeAg-positive chronic hepatitis B. Patients must be ≥18 years old and have compensated liver disease.

[PegInon Drug Toxicology]

Pharmacological effects of peginterferon alpha-2b are recombinant human interferon alpha-2b and monomethoxypolyethylene glycol A covalent conjugate with an average molecular weight of approximately 31,300 daltons. Recombinant human interferon alpha-2b is obtained by expressing the interferon alpha-2b gene of human leukocytes in recombinant Escherichia coli. In vitro and in vivo research results suggest that the biological activity of peginterferon alpha-2b comes from the recombinant human interferon alpha-2b part of its structure. Interferons work by binding to specific membrane receptors on the cell surface. Other interferon studies suggest that interferons are species-specific. In some primates, such as rhesus monkeys, there is a pharmacodynamic response after administration of human type 1 interferon. Once interferon binds to the cell membrane, it can initiate a series of complex intracellular processes, including inducing the expression of certain enzymes. This process is at least partly responsible for the cellular response to interferon, including inhibiting viral replication in virus-infected cells, increasing cell proliferation, enhancing macrophage phagocytosis, and increasing lymphocyte-specific cytotoxicity. A series of immune regulatory activities. Any or all of these responses may be related to the therapeutic effects of interferon. Recombinant human interferon α-2b can inhibit viral replication both in vivo and in vitro. The mechanism of its antiviral effect is unclear and may be related to changing the metabolism of host cells. This effect can inhibit viral replication, or prevent progeny viruses from leaving the cell after viral replication.

Toxicological studies No adverse events were observed in clinical trials of peginterferon α-2b, nor in monkey toxicity studies. Star toxicities that emerged in monkey toxicity studies included leukopenia. Reproductive toxicity studies of peginterferon alfa-2b have not been conducted, but studies have shown that interferon alfa-2b can cause abortion in pregnant primates, so peginterferon alfa-2b may have similar effects. effect. In acute toxicity tests and subacute toxicity tests in rodents and monkeys, in vitro genetic toxicity tests, and perinatal reproductive toxicity tests, monomethoxypolyethylene glycol showed no toxicity.

【PegIntron Leneng usage and dosage]

Chronic hepatitis C: subcutaneous injection, once a week. For those weighing less than 65kg, 40μg each time. For those weighing 65kg or above, 50μg each time. Take ribavirin orally at the same time. The usage and dosage of ribavirin are shown in the table below (based on 150 mg per pill) Body weight (kg) Daily dose (mg) Capsules (capsules/day) 50-60 750 5 capsules (3 capsules in the morning, 2 capsules in the evening) 65-80 900 6 pills (3 pills in the morning, 3 pills in the evening) 85-90 1050 7 pills (4 pills in the morning, 3 pills in the evening) Treatment course: After 6 months of medication, if the viral load is still high, it is recommended to stop medication. Dose adjustment: If serious adverse reactions and abnormal laboratory indicators occur during treatment, it is recommended to adjust the dose appropriately until the adverse reactions disappear or are alleviated. Principles for dose adjustment of this product Laboratory examination Reduce dose Terminate treatment White blood cells <2.5×109/L <2.5×109/L Neutrophils <1.0×109/L <0.75×109/L Platelets <50×109/L < 25×109/L Creatinine >2.0 mg/dl (or >176.8 μmol/L) ALT 2 times the basic value or >10 times the normal value Indirect bilirubin 3 mg/dl (or >51 μmol/L) 4 weeks direct bilirubin Hemoglobin <80g/L >2.5 times the normal value. Patients with heart disease: <120g/L after 4 weeks of dose reduction. Method for dose adjustment of this product. Body weight. Current dose. Adjusted dose >65kg 50μg 25μg <65kg 40μg 20μg Ribavirin dose Adjustment principles Laboratory tests Reduce dose Discontinue treatment Hemoglobin <90g/L <80g/L Patients with heart disease: Patients with heart disease during treatment: Decrease ≥20g/L within any 4 weeks Dose <120g/L after 4 weeks White blood cells (WBC) ＜2.0×109/L Granulocytes ＜0.75×109/L Platelets ＜25×109/L Creatinine ＞2.0mg/dl (or ＞176.8μmol/L) ALT 2 times the basic value or ＞10 times normal Value indirect bilirubin>3mg/dL (or>51μmol/L) 3mg/dL (or>51μmol/L) (more than 4 weeks) Direct bilirubin>2.5 times normal value Ribavirin dose adjustment method Ribavir The total number of capsules per day is reduced for the first time and for the second time, 750mg/day: 3 capsules in the morning and 2 capsules in the evening. 4 capsules/day (600mg/day) 3 capsules/day (450mg/day): 2 capsules in the morning and 2 capsules in the evening. 2 pills in the morning, 1 pill in the evening 900mg/day 3 pills in the morning, 3 pills in the evening 5 pills/day (750mg/day) 4 pills/day (600mg/day) 3 pills in the morning, 2 pills in the evening 2 pills in the morning, 2 pills in the evening 1050mg 4 pills/day in the morning, 3 pills in the evening, 6 pills/day (900mg/day) 5 pills/day (750mg/day) 3 pills in the morning, 3 pills in the evening, 3 pills in the morning, 2 pills in the evening. Adjust the dosage according to the indirect bilirubin test results. Specific standards for the dosage of bavirin: the first reduction when indirect bilirubin is >3 mg/dL (or >51 μmol/L), and the second reduction if indirect bilirubin is still greater than 3 mg/dL after 1-2 weeks of reduction. If the indirect bilirubin is greater than 3 mg/dL for four consecutive weeks, stop ribavirin. Ribavirin alone should be discontinued for at least one week and up to two weeks. If the indirect bilirubin drops to <2.5 mg/dL after stopping the drug, the ribavirin dose can be returned to the dose before the drug was stopped. If indirect bilirubin remains <2.5 mg/dL for more than four weeks, the dose of ribavirin can be adjusted to the full dose. Specific standards for adjusting the dosage of ribavirin based on hemoglobin test results: The first dose reduction when hemoglobin is <90g/L. If the hemoglobin is still below 90g/L after 1-2 weeks of dose reduction, the second dose reduction. If there is If the hemoglobin is less than 80g/L, discontinue ribavirin. Ribavirin alone should be discontinued for at least one week and up to two weeks. If the hemoglobin is >80g/L after stopping the drug, the dose of ribavirin before stopping the drug can be restored. If hemoglobin remains >90g/L for more than four weeks, the dose of ribavirin can be adjusted to the full dose. For patients whose laboratory test indicators return to normal through dose adjustment, the dose should be readjusted to the full dose; for patients whose laboratory tests have not returned to normal by 20 weeks after dose adjustment, the reduced dose should be maintained. 2. Chronic hepatitis B: The current recommended dose is 1.0 μg/kg, once a week, subcutaneous injection. Treatment duration: 24 weeks. Other doses and regimens have not been adequately studied. Dose adjustment: Principle of dosage adjustment of this product: Reduce the hematological and biochemical parameters of this product to half the dose and suspend the use of this product. White blood cells (WBC) ＜1.5×109/L ＜1.0×109/L Granulocytes ＜0.75×109/L ＜0.5× 109/L Platelets ＜50×109/L ＜25×109/L Creatinine N/A ＞2.0mg/dL (or＞176.8μmol/L) ALT N/A ＞10 times the upper limit of normal value Total bilirubin N/A ≥2 times the upper limit of normal value (combined with clinical symptoms such as fatigue) The dose adjustment method of this product is based on body weight. Current dose (100 μg/tube, ml) Reduced dose (100 μg/tube, ml) ≤69kg 0.25-0.30 0.15 70-89kg 0.35 -0.40 0.20 ≥90kg 0.45-0.50 0.25 Drug preparation and usage: This product is white and tablet-like before dissolving, in the form of a whole piece, multiple fragments, or powder. Each vial must be dissolved with 0.7 ml of sterile solvent and 0.5 ml must be withdrawn for injection. Use a sterile syringe and a long needle to extract 0.7ml of solvent, and slowly inject the solvent into the ampoule of this product along the bottle wall. It is best not to point the solvent directly at the product, and do not inject too fast, because this will produce a lot of bubbles. Within a few minutes after dissolution, the product will appear in the form of clouds or multiple small bubbles. Gently turn the ampoule to dissolve completely. Do not shake vigorously. Since a small amount of this product will be lost when extracting the dissolved product, in order to ensure that the injected dose is consistent with the dose on the label, the actual content of this product and solvent exceeds the content of the specification. The extracted 0.5ml of this product is the label content on. The concentrations of each specification of this product are: 50μg/0.5ml, 80μg/0.5ml, 100μg/0.5ml.

Picture Jiejing Xint Pharmacy Network warmly reminds you: In order to achieve better therapeutic effects and ensure medication safety, it is recommended that you please Consult a specialist or specialist pharmacist first to learn more about the drug treatment options for the disease. If you want to know more about the efficacy of PegIntron (peginterferon alpha-2b injection), where can you buy it? For the latest PegIntron (Peginterferon α-2b injection) discount plan, please feel free to call the pharmacist service hotline of Jiejing Xint Pharmacy at 400-080-3980. For more cost-effective treatment options, please visit Jiejing Xint Pharmacy website (http://www.jjxt.com.cn).